Status:
COMPLETED
Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)
Lead Sponsor:
Thomas Jefferson University
Collaborating Sponsors:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
March of Dimes
Conditions:
Preeclampsia
Eligibility:
FEMALE
10-60 years
Brief Summary
This proposal has three aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of hypertensive disorders of pregnancy (HDP) through a prospective, co...
Detailed Description
This proposal has four aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of HDP through a prospective, cohort study using pharmacodynamics, phar...
Eligibility Criteria
Inclusion
- Pregnant singleton, \<16 weeks' gestation
- At least one high risk factor for preeclampsia: prior preeclampsia, chronic hypertension, pregestational diabetes, chronic kidney disease, lupus, antiphospholipid antibody syndrome
Exclusion
- Contraindication to aspirin
- Current or planned use of any other anticoagulation
- Use of aspirin in pregnancy prior to enrollment
- Known platelet disorder at time of enrollment
Key Trial Info
Start Date :
August 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04295850
Start Date
August 21 2020
End Date
June 30 2023
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107